Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IceCure Medical (ICCM) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for IceCure Medical (ICCM) over the last 6 years, with Q3 2025 value amounting to $60.6 million.

  • IceCure Medical's Shares Outstanding (Diluted Average) rose 2318.56% to $60.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.6 million, marking a year-over-year increase of 2318.56%. This contributed to the annual value of $50.9 million for FY2024, which is 1147.89% up from last year.
  • IceCure Medical's Shares Outstanding (Diluted Average) amounted to $60.6 million in Q3 2025, which was up 2318.56% from $120.0 recorded in Q2 2025.
  • Over the past 5 years, IceCure Medical's Shares Outstanding (Diluted Average) peaked at $60.6 million during Q3 2025, and registered a low of $120.0 during Q2 2025.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $36.6 million, with a median of $37.0 million in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 8030.84% in 2021, then crashed by 9999.97% in 2024.
  • Quarter analysis of 5 years shows IceCure Medical's Shares Outstanding (Diluted Average) stood at $28.5 million in 2021, then increased by 29.66% to $37.0 million in 2022, then increased by 23.29% to $45.6 million in 2023, then grew by 11.48% to $50.9 million in 2024, then rose by 19.05% to $60.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $60.6 million in Q3 2025, compared to $120.0 in Q2 2025 and $57.6 million in Q1 2025.